Xcision Medical Systems

Executive Summary

Xcision Medical Systems is a privately held medical device company headquartered in Columbia, Maryland, focused on revolutionizing breast cancer radiotherapy with its proprietary GammaPod system. GammaPod is designed to deliver stereotactic radiotherapy (SBRT) for breast cancer in one to five sessions, offering a more efficient, cost-effective, and patient-friendly alternative to conventional and hypofractionated regimens. The technology addresses a critical unmet need in breast cancer treatment by reducing treatment duration and improving patient comfort while maintaining clinical efficacy. Founded in 2009, Xcision operates in the radiopharmaceuticals and radiotherapy space but remains in a pre-revenue stage with no disclosed funding rounds, valuation, or employee count. The company has yet to achieve FDA clearance or commercial adoption, though its platform has the potential to disrupt standard-of-care breast radiotherapy if validated through clinical evidence and regulatory approvals.

Upcoming Catalysts (preview)

• 2026FDA 510(k) Clearance or De Novo Classification for GammaPod60% success
• 2026Publication of Pivotal Clinical Trial Results in Peer-Reviewed Journal50% success
• TBDStrategic Partnership or Licensing Agreement with Major Radiation Oncology Provider30% success